# Fentanyl Transdermal Matrix Patch ZR-02-01 to Treat Moderate to Severe Cancer Pain

> **NCT00126789** · PHASE3 · TERMINATED · sponsor: **ZARS Pharma Inc.** · enrollment: 24 (actual)

## Conditions studied

- Pain
- Cancer

## Interventions

- **DRUG:** Fentanyl Transdermal Matrix Patch ZR-02-01

## Key facts

- **NCT ID:** NCT00126789
- **Lead sponsor:** ZARS Pharma Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2005-08
- **Primary completion:** 2007-07
- **Final completion:** 2007-07
- **Target enrollment:** 24 (ACTUAL)
- **Why stopped:** Based on PK data, product did not meet requirement for further development.
- **Last updated:** 2012-06-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00126789

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00126789, "Fentanyl Transdermal Matrix Patch ZR-02-01 to Treat Moderate to Severe Cancer Pain". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00126789. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*